0001104659-21-089437.txt : 20210706 0001104659-21-089437.hdr.sgml : 20210706 20210706162739 ACCESSION NUMBER: 0001104659-21-089437 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210701 FILED AS OF DATE: 20210706 DATE AS OF CHANGE: 20210706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katabi Maha CENTRAL INDEX KEY: 0001720685 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 211074427 MAIL ADDRESS: STREET 1: SOFINNOVA INVESTMENTS STREET 2: 3000 SAND HILL ROAD, 4-250 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 4 1 tm2121485-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-07-01 0 0001798749 Aerovate Therapeutics, Inc. AVTE 0001720685 Katabi Maha C/O AEROVATE THERAPEUTICS, INC. 200 BERKELEY STREET, FLOOR 18 BOSTON MA 02116 1 0 1 0 Common Stock 2021-07-02 4 C 0 3401544 A 3401544 I By Sofinnova Venture Partners X, L.P. Common Stock 2021-07-02 4 P 0 357142 14 A 3758686 I By Sofinnova Venture Partners X, L.P. Stock Option (Right to Buy) 19.41 2021-07-01 4 A 0 2467 11.147 A 2031-06-30 Common Stock 2467 2467 D Series A Preferred Stock 2021-07-02 4 C 0 10565238 D Common Stock 3401544 0 I By Sofinnova Venture Parnters X, L.P. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein. This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021. /s/ George A. Eldridge, Attorney-in-Fact 2021-07-06